Formulation and Evaluation of Fast Dissolving Tablet of Lasmiditan

The objective of the present research was the formulation and evaluation of fast dissolving tablets (FDTs) of Lasmiditan, a 5-HT (1F) receptor agonist, for the acute treatment of migraine, with the aim of achieving a rapid onset of therapeutic action and improved patient compliance. Lasmiditan has poor aqueous solubility; therefore, fast dissolution is essential to ensure quick absorption and relief. Eight formulations (F1–F8) were developed using wet granulation. The concentration of crospovidone and croscarmellose sodium was varied to assess their influence on tablet performance. Other excipients, such as microcrystalline cellulose (MCC), mannitol, polyvinylpyrrolidone (PVP K30, binder), and flavoring agents, were kept constant. All formulations were evaluated for pre- and postcompression parameters, including organoleptic properties, hardness, friability, weight variation, drug content, disintegration time, wetting time, water absorption ratio, and in vitro drug release. The results revealed that all formulations complied with pharmacopeial limits. However, formulation F5, which exhibited the shortest disintegration time and 90% drug release within 15 minutes. This made it the most optimized batch. Drug-excipient compatibility was confirmed by FTIR analysis, which showed no significant interaction. Stability studies conducted on the optimized formulation under ICH guidelines revealed no significant changes in tablet characteristics over time. The optimized lasmiditan FDT (F5) offers rapid disintegration and drug release, making it a promising dosage form for effectively and immediately managing migraines and potentially improving patient adherence and therapeutic efficacy.